Sanofi

News

Lilly bets $2.4bn on Dice’s immune disease platform

Eli Lilly has struck a $2.4 billion deal to buy Dice Therapeutics and its drug discovery and development platform for oral, small molecule therapies for immunological dise

News

Boehringer loses bid to be shielded from Zantac litigation

Sanofi says it has won an arbitration dispute with Boehringer Ingelheim, in which the latter had tried to protect itself from liabilities that may arise from ongoing litig

News

FDA advisors back Beyfortus for RSV prevention

An FDA advisory committee has voted in favour of approving AstraZeneca and Sanofi’s one-shot antibody treatment to prevent respiratory syncytial virus (RSV) disease in inf

News

Sanofi scores in MS with CD40 antibody frexalimab

Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L

Oncology

Sanofi is calling for a comprehensive, UK guideline to impro...

Non-melanoma skin cancer (NMSC) is the most common cancer in the UK, with more than 155,000 cases of NMSC reported in the UK every year.1,2 However, NMSC is significantly under-r

News

Sanofi, Regeneron flesh out COPD data with Dupixent

Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (AT

Lilly bets $2.4bn on Dice’s immune disease platform

Boehringer loses bid to be shielded from Zantac litigation

FDA advisors back Beyfortus for RSV prevention

Sanofi scores in MS with CD40 antibody frexalimab

Sanofi is calling for a comprehensive, UK guideline to impro...

Sanofi, Regeneron flesh out COPD data with Dupixent

AZ claims another win for Imfinzi in frontline liver cancer

Using AI-driven synthetic personas to take your insights fur...

Sanofi

Editor's Picks